Nrf2 Induces Cisplatin Resistance Via Suppressing the Iron Export Related Gene SLC40A1 in Ovarian Cancer Cells

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Dec 8

PMID 29212168

Citations 36

Authors

Jianfa Wu

Lingjie Bao

Zhenbo Zhang

Xiaofang Yi

Affiliations

Soon will be listed here.

Abstract

Induction of Nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) has been demonstrated to be involved in cisplatin resistance in ovarian cancer. Solute carrier family 40 member 1 (SLC40A1) is an iron exporter, which possesses many putative Nrf2 binding sites. Here we hypothesize that it may be a possible downstream gene of Nrf2. Elevated level of Nrf2 and reduced level of SLC40A1 were found in cisplatin-resistant ovarian cancer cells as compared with cisplatin-sensitive ovarian cancer cells. Exogenous knockdown of Nrf2 leaded to increased expression of SLC40A1. While overexpression of Nrf2 resulted in decreased expression of SLC40A1. Chromatin immunoprecipitation (ChIP) and dual-luciferase reporter assay revealed that Nrf2 inhibited the transcription of SLC40A1. Overexpression of SLC40A1 was able to reverse cisplatin resistance induced by Nrf2, while knockdown of SLC40A1 restored cisplatin resistance and increased iron concentration. Desferal, an iron chelator, was found to overcome cisplatin resistance through iron deprivation. Its function was boosted when combined with brusatol, an Nrf2 inhibitor. Taken together, this study first demonstrated that Nrf2 could transcriptionally suppress the expression of SLC40A1. Iron overload induced by SLC40A1 resulted in cisplatin resistance in ovarian cancer. Targeting iron metabolism may be a new therapeutic strategy to reverse drug resistance in ovarian cancer treatment.

Citing Articles

-Substituted AB-type phenothiazinyl porphyrins and their indium and zinc complexes photosensitising properties, cytotoxicity and phototoxicity on ovarian cancer cells.

Balazs B, Stoean Vasile B, Molnar E, Fischer-Fodor E, Balacescu O, Borlan R RSC Med Chem. 2024; 16(2):747-766.

PMID: 39568597 PMC: 11575637. DOI: 10.1039/d4md00601a.

NFE2L2 and ferroptosis resistance in cancer therapy.

Tang D, Kang R Cancer Drug Resist. 2024; 7:41.

PMID: 39534872 PMC: 11555182. DOI: 10.20517/cdr.2024.123.

Leonurine: a comprehensive review of pharmacokinetics, pharmacodynamics, and toxicology.

Liu S, Sun C, Tang H, Peng C, Peng F Front Pharmacol. 2024; 15:1428406.

PMID: 39101131 PMC: 11294146. DOI: 10.3389/fphar.2024.1428406.

Redox-Regulated Iron Metabolism and Ferroptosis in Ovarian Cancer: Molecular Insights and Therapeutic Opportunities.

Liu D, Hu Z, Lu J, Yi C Antioxidants (Basel). 2024; 13(7).

PMID: 39061859 PMC: 11274267. DOI: 10.3390/antiox13070791.

Ferroptosis regulation by Cap'n'collar family transcription factors.

Murray M, Dixon S J Biol Chem. 2024; 300(8):107583.

PMID: 39025451 PMC: 11387702. DOI: 10.1016/j.jbc.2024.107583.

References

Lattuada D, Uberti F, Colciaghi B, Morsanuto V, Maldi E, Squarzanti D . Fimbrial cells exposure to catalytic iron mimics carcinogenic changes. Int J Gynecol Cancer. 2015; 25(3):389-98. DOI: 10.1097/IGC.0000000000000379. View

Hann H, Stahlhut M, Blumberg B . Iron nutrition and tumor growth: decreased tumor growth in iron-deficient mice. Cancer Res. 1988; 48(15):4168-70. View

Wessling-Resnick M . Nramp1 and Other Transporters Involved in Metal Withholding during Infection. J Biol Chem. 2015; 290(31):18984-90. PMC: 4521020. DOI: 10.1074/jbc.R115.643973. View

Bai X, Chen Y, Hou X, Huang M, Jin J . Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters. Drug Metab Rev. 2016; 48(4):541-567. DOI: 10.1080/03602532.2016.1197239. View

Funakoshi N, Chaze I, Alary A, Tachon G, Cunat S, Giansily-Blaizot M . The role of genetic factors in patients with hepatocellular carcinoma and iron overload - a prospective series of 234 patients. Liver Int. 2015; 36(5):746-54. DOI: 10.1111/liv.12984. View

Benyamin B, Esko T, Ried J, Radhakrishnan A, Vermeulen S, Traglia M . Novel loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis. Nat Commun. 2014; 5:4926. PMC: 4215164. DOI: 10.1038/ncomms5926. View

Wang Y, Wang Y, Zhang Z, Park J, Guo D, Liao H . Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway. Oncotarget. 2016; 7(9):10363-72. PMC: 4891125. DOI: 10.18632/oncotarget.7004. View

Khalil H, Goltsov A, Langdon S, Harrison D, Bown J, Deeni Y . Quantitative analysis of NRF2 pathway reveals key elements of the regulatory circuits underlying antioxidant response and proliferation of ovarian cancer cells. J Biotechnol. 2014; 202:12-30. DOI: 10.1016/j.jbiotec.2014.09.027. View

Ye F, Li X, Li L, Yuan J, Chen J . t-BHQ Provides Protection against Lead Neurotoxicity via Nrf2/HO-1 Pathway. Oxid Med Cell Longev. 2016; 2016:2075915. PMC: 4698940. DOI: 10.1155/2016/2075915. View

10.

Castiella A, Zapata E, de Juan M, Zubiaurre L, Iribarren A, Otazua P . Analysis of HFE mutations and non-HFE gene mutations (TFR2 and SLC40A1) in patients with phenotypic hemochromatosis from the Basque Country. Int J Lab Hematol. 2015; 38(1):e5-7. DOI: 10.1111/ijlh.12444. View

11.

Rao V, Klein S, Agama K, Toyoda E, Adachi N, Pommier Y . The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells. Cancer Res. 2009; 69(3):948-57. PMC: 7322628. DOI: 10.1158/0008-5472.CAN-08-1437. View

12.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

13.

Li J, Yang S, Su N, Wang Y, Yu J, Qiu H . Overexpression of long non-coding RNA HOTAIR leads to chemoresistance by activating the Wnt/β-catenin pathway in human ovarian cancer. Tumour Biol. 2015; 37(2):2057-65. DOI: 10.1007/s13277-015-3998-6. View

14.

Le Gac G, Ka C, Joubrel R, Gourlaouen I, Lehn P, Mornon J . Structure-function analysis of the human ferroportin iron exporter (SLC40A1): effect of hemochromatosis type 4 disease mutations and identification of critical residues. Hum Mutat. 2013; 34(10):1371-80. DOI: 10.1002/humu.22369. View

15.

Zhou Q, Chen B, Wang X, Wu L, Yang Y, Cheng X . Sulforaphane protects against rotenone-induced neurotoxicity in vivo: Involvement of the mTOR, Nrf2, and autophagy pathways. Sci Rep. 2016; 6:32206. PMC: 4995453. DOI: 10.1038/srep32206. View

16.

Pajares M, Jimenez-Moreno N, Garcia-Yague A, Escoll M, de Ceballos M, Van Leuven F . Transcription factor NFE2L2/NRF2 is a regulator of macroautophagy genes. Autophagy. 2016; 12(10):1902-1916. PMC: 5079676. DOI: 10.1080/15548627.2016.1208889. View

17.

Torti S, Torti F . Iron and cancer: more ore to be mined. Nat Rev Cancer. 2013; 13(5):342-55. PMC: 4036554. DOI: 10.1038/nrc3495. View

18.

Vugts D, Klaver C, Sewing C, Poot A, Adamzek K, Huegli S . Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for Zr-immuno-PET. Eur J Nucl Med Mol Imaging. 2016; 44(2):286-295. PMC: 5215071. DOI: 10.1007/s00259-016-3499-x. View

19.

Shen C, Cheng W, Yu P, Wang L, Zhou L, Zeng L . Resveratrol pretreatment attenuates injury and promotes proliferation of neural stem cells following oxygen-glucose deprivation/reoxygenation by upregulating the expression of Nrf2, HO-1 and NQO1 in vitro. Mol Med Rep. 2016; 14(4):3646-54. PMC: 5042764. DOI: 10.3892/mmr.2016.5670. View

20.

Habel M, Jung D . c-Myc over-expression in Ramos Burkitt's lymphoma cell line predisposes to iron homeostasis disruption in vitro. Biochem Biophys Res Commun. 2006; 341(4):1309-16. DOI: 10.1016/j.bbrc.2006.01.097. View